Singapore is the first ASEAN country to provide government subsidy for eligible patients receiving vutrisiran for transthyretin amyloidosis
"From September 2026 – eligible patients receiving vutrisiran will receive government subsidies of up to 75%[1],[2]" "HELIOS-A and B provide strong clinical evidence supporting improved patient outcomes" SINGAPORE, Sept. 1, 2026 /PRNewswire/ — Medison Pharma (Medison), the creator of a first-of-its-kind unified global commercialisation platform for breakthrough therapies, today announced that from September 1st, 2026, […]





